Minimal Residual Disease (MRD)-Guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB Non-small Cell Lung Cancer (NSCLC): a Randomized Controlled Phase II Study (Seagull)
Latest Information Update: 20 Mar 2023
At a glance
- Drugs Tislelizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Mar 2023 Protocol of study has been amended to change number of treatment arm from 1 to 2, to add randomized and parallel system in trial design, and to primary endpoint is changed to PFS
- 15 Mar 2023 Status changed from not yet recruiting to recruiting.
- 15 Mar 2023 Planned number of patients changed from 30 to 60.